BioTech AEMD Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments August 28, 2026 — 03:14 pm EDT Written by RTTNews.com for RTTNews linkedin facebook x email reddit (RTTNews) - Today's top gainers in the biotech and healthcare space include Aethlon Medical, following narrower quarterly losses and progress in its Hemopurifier oncology study; Quoin Pharmaceuticals, on positive QRX003 data and a $50 million financing; Dogwood Therapeutics, as its Halneuron Phase 2b trial advances toward a fall readout; and Freenome, after receiving FDA Breakthrough Device Designation for its lung cancer screening test. Read on... AEMD Shares Jump As Q1 Loss Narrows 12%, Hemopurifier Program Advances Aethlon Medical, Inc. (AEMD) shares jumped after the company reported a 12% year-over-year narrowing in its Q1 loss to $1.55 million, compared with $1.76 million a year earlier. Operating expenses declined to $1.58 million from $1.79 million, while interest income rose to $31.29 million from $30.53 million. Aethlon also dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia, with preliminary data showing reductions in tumor-derived extracellular vesicles and cancer-associated microRNAs. AEMD shares are currently trading at $2.54, up 17.5%. QNRX Surges 34% Pre-Market On Positive QRX003 Data, $50M Financing Quoin Pharmaceuticals, Inc. (QNRX) shares surged 34% in pre-market trading after the company reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome and announced a private placement of up to $50 million. The first six patients completing 12 weeks of treatment met the pre-specified primary endpoint, with four patients achieving at least a one-grade improvement in Investigator Global Assessment. The financing includes approximately $30.8 million in upfront proceeds and up to $19.2 million from potential warrant exercises to support QRX003 development and operations. QNRX shares are currently trading at $6.60, up 28.70%. DWTX Gains 12% As Halneuron Phase 2b Trial Advances Toward Fall Readout Dogwood Therapeutics, Inc. (DWTX) shares gained 12% after the company reported second-quarter 2026 results and provided an update on its lead candidate Halneuron in a Phase 2b trial for chemotherapy-induced neuropathic pain. The company has enrolled 217 patients in the study and expects to report topline results in fall 2026, with enrollment expected to exceed 220 patients. Dogwood also launched a 12-week long-term extension study to evaluate Halneuron's pain reduction over three months of treatment. For Q2, R&D expenses increased to $3.2 million from $2.6 million, while net loss widened to $11.5 million from $3.8 million, primarily reflecting a $6.7 million non-cash impairment charge. Dogwood ended the quarter with $9.6 million in cash, providing an operational runway through the Phase 2b readout. DWTX shares are currently trading at $2.61, up 12.61%. FRNM Gains 7% On FDA Breakthrough Device Designation For Lung Cancer Test Freenome, Inc. (FRNM) shares gained 6.67% after the FDA granted Breakthrough Device Designation to its investigational SimpleScreen Lung blood-based test for early lung cancer screening. The AI-powered multiomic test is being developed for adults ages 50 to 80 at high risk of lung cancer who are not currently participating in recommended screening. SimpleScreen Lung combines methylation and proteomics technologies with an AI/ML-powered classifier to detect signals associated with lung cancer from a standard blood sample. Freenome said the designation provides prioritized review and interactive communication with the FDA as it advances clinical development toward a potential regulatory submission. FRNM shares are currently trading at $14.95, up 7.03%. RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source facebook x website Tags BioTech Stocks Mentioned AEMD Latest Articles Data is currently not available